X4 Pharmaceuticals (XFOR) Free Cash Flow (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Free Cash Flow for 10 consecutive years, with -$20.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 30.44% year-over-year to -$20.8 million; the trailing twelve-month figure through Jun 2026 stood at -$84.2 million (up 22.92% YoY), and the FY2025 full-year result was -$86.1 million, up 35.92% from the prior year.
• Free Cash Flow declined to -$20.8 million in Q2 2026 per XFOR's latest filing, from -$19.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$12.4 million in Q1 2025 and bottomed at -$68.8 million in Q3 2023.
• Historically, Free Cash Flow has averaged -$30.2 million across 5 years, with a median of -$27.2 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 256.24% in 2023, then jumped 63.25% in 2025.
• Over 5 years, Free Cash Flow stood at -$19.1 million in 2022, then plunged by 45.25% to -$27.8 million in 2023, then retreated by 18.76% to -$33.0 million in 2024, then surged by 51.45% to -$16.0 million in 2025, then decreased by 29.85% to -$20.8 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$20.8 million, -$19.6 million, and -$16.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.